Alpha Teknova, Inc.

NASDAQ · TKNO
7.36−0.73−9.02%as of Oct 30, 2026

Alpha Teknova, Inc. (referred to herein as the Company, Teknova, we, us or our) is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our more than 3,000 customers span the continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our manufacturing processes and infrastructure, which are highly adaptable and configurable. These proprietary processes enable us to manufacture and deliver high-quality, custom, made-to-order products with short turnaround times and at scale, across all stages of our customers’ product development, including commercialization. We have substantial expertise in manufacturing customer-specified formulations and have demonstrated the ability to manufacture and deliver our products to customers quickly. Due to our expertise in raw materials sourcing, chemical formulation, and quality control, developed over more th

From the 10-K filed Mar 2, 2026

CEO
Mr. Stephen Gunstream
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
158
Headquarters
Hollister, CA
Fiscal year end
December
1 year+2.30 (+45.45%)
TKNO+45.45%
$2.00$4.00$6.00$8.00
$7.36
10MVol
Oct '25Jan '26Mar '26Jun '26Aug '26Oct '26
FundalyzePowered by fundalyze.ai
1.919.48

as of Oct 22, 2026 · today 7.36, 72% of the way from low to high

No dividends on record.

A company that pays none, or whose history has not arrived yet, shows nothing here.

Valuation

Market cap$395.10Mas of Oct 22, 2026
P/E-23.6×TTM · Q3 2025 – Q2 2026
P/S9.0×TTM · Q3 2025 – Q2 2026
P/B6.3×Q2 2026
Dividend yield—no dividends on record

Results, trailing twelve months

Revenue$43.70MTTM · Q3 2025 – Q2 2026
Net income-$16.77MTTM · Q3 2025 – Q2 2026
Diluted EPS-$0.31TTM · Q3 2025 – Q2 2026
Gross margin34.6%TTM · Q3 2025 – Q2 2026

Balance and cash

Enterprise value$390.89Mas of Oct 22, 2026
Long-term debt$13.22MQ2 2026
Free cash flow-$7.35MTTM · Q3 2025 – Q2 2026
Stock-based comp.$2.94MTTM · Q3 2025 – Q2 2026

Shares and market

Shares outstanding53.68Mas of Oct 23, 2026
Average volume1.21Mshares a day, last 3 months
Beta0.858

Financial statements

Loss before income taxes +35.9% −$26.83M → −$17.20M, year ended Dec 31, 2025

Comps

Valuation, growth and margins against the closest competitors

Filings

10-K filed Mar 2, 2026 · 10-Q Aug 6, 2026

FilingFiled
10-Q for Quarter Ended June 2026Aug 6, 2026
10-Q for Quarter Ended March 2026May 7, 2026
10-K for Fiscal Year Ended December 2025Mar 2, 2026
10-Q for Quarter Ended September 2025Nov 7, 2025

Insiders

$40.51K sold $143.42K bought · open market, 12 months to Mar 6, 2026

InsiderTypeValue
Stephen GunstreamMar 6, 2026Purchase$55.80K ↗
Matthew LowellMar 6, 2026Purchase$87.62K ↗
Martha J DemskiJun 27, 2025Sale$40.51K ↗

Funds (13F)

17.0% held by 84 managers · as of Sep 30, 2026

ManagerValueChange
ROYCE & ASSOCIATES LP$9.44M+592.23K (+55.4%)
VANGUARD CAPITAL MANAGEMENT LLC$9.17M+1.17M (+265.3%)
Roubaix Capital, LLC$8.97M−302.95K (−16.1%)
BlackRock, Inc.$5.00M+163.01K (+22.7%)
UBS Group AG$3.59M+306.80K (+94.4%)

Congress

92 trades 91 sales · 1 purchases · 1 members, 12 months

MemberTypeAmount
Richard BlumenthalAug 12, 2026Sale$1K–$15K
Richard BlumenthalAug 12, 2026Sale$1K–$15K
Richard BlumenthalAug 12, 2026Sale$1K–$15K
Richard BlumenthalAug 12, 2026Sale$1K–$15K

Short interest

15.01% of float · 5.82 days to cover · Oct 15, 2026

Short position, last two years · 48% of its 2-year range

Source: FINRA

No headlines in the business press in the last 30 days.

Company data reported to the SEC on EDGAR (CIK 1850902).

Everything on TKNO, in full

Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.

Start your free trial